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Exacerbation of Celecoxib-Induced Renal Injury by
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Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) can produce adverse effects by inhibiting prostaglandin (PG) synthesis. A
PGE1 analogue, misoprostol, is often utilized to alleviate NSAID-related gastrointestinal side effects. This study examined the
effect of misoprostol on celecoxib renal toxicity. Additionally, the effects of these drugs on cardiovascular parameters were
evaluated. Four randomized rat groups were orally gavaged for 9 days, two groups receiving vehicle and two groups
receiving misoprostol (100 mg/kg) twice daily. Celecoxib (40 mg/kg) was co-administered once daily to one vehicle and one
misoprostol group from days 3 to 9. Urine and blood samples were collected and blood pressure parameters were
measured during the study period. Hearts and kidneys were harvested on final day. Day 2 urinary electrolyte samples
revealed significant reductions in sodium excretion in misoprostol (0.1260.05 mmol/min/100 g) and misoprostol+celecoxib
groups (0.0760.02 mmol/min/100 g). At day 3, all treatment groups showed significantly reduced sodium excretion.
Potassium excretion diminished significantly in vehicle+celecoxib and misoprostol+celecoxib groups from day 3 onward.
Urinary kidney injury molecule-1 levels were significantly increased in vehicle+celecoxib (0.6560.02 vs. 0.3560.07 ng/mL,
p = 0.0002) and misoprostol+celecoxib (0.6160.06 vs. 0.3760.06 ng/mL, p = 0.0015) groups when compared to baseline;
while plasma levels of cardiac troponin I increased significantly in vehicle+celecoxib (p = 0.0040) and misoprostol+
misoprostol (p = 0.0078) groups when compared to vehicle+vehicle. Blood pressure parameters increased significantly in all
misoprostol treated groups. Significant elevation in diastolic (p = 0.0071) and mean blood pressure (p = 0.0153) was noted in
misoprostol+celecoxib compared to vehicle+celecoxib. All treatments produced significant tubular dilatation/necrosis
compared to control. No significant myocardial changes were noticed; however, three animals presented with pericarditis.
Kidney, heart, and plasma celecoxib levels revealed no significant change between vehicle+celecoxib and misoprostol+
celecoxib. Concomitant misoprostol administration did not prevent celecoxib renal toxicity, and instead exacerbated renal
side effects. Misoprostol did not alter plasma or tissue celecoxib concentrations suggesting no pharmacokinetic interaction
between celecoxib and misoprostol.
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include stomach bleeding, indigestion, and ulceration. Edema and
electrolyte retention are the predominant NSAID-related renal
side effects [3–7]. It has also been found that individuals who
present with cardiovascular (CV) complications may be at an
increased risk of developing myocardial infarction (MI) or stroke,
when undergoing prolonged NSAID therapy [8–11].
NSAIDs can produce toxic effects in both the GI and renal
systems. Furthermore, several studies have established a link
between COXIBs and CV adverse events [12]. COXIBs (e.g.
celecoxib) were found to cause sodium retention by increasing the
expression of Na+/K+/2Cl2 cotransporter (NKCC2) in renal
tubules. Another transporter heavily involved in sodium regulation, Na+/K+-ATPase (NKA), may fluctuate with changing PG
levels contributing to sodium retention [13,14]. A decrease in

Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are highly
efficient drugs used in a variety of diseases because of their antiinflammatory, antipyretic, and analgesic effects. NSAIDs function
through the inhibition of cyclooxygenase (COX), an enzyme
necessary for prostaglandin (PG) formation. NSAIDs are categorized based on their specific mechanism of action. Non-selective
NSAIDs, such as diclofenac and indomethacin, function to inhibit
both COX-1 and COX-2 enzymes; while COX-2-selective
inhibitors (COXIBs), such as celecoxib and rofecoxib, function
to inhibit only the COX-2 enzyme [1,2].
Because of the highly efficient nature of NSAIDs, a large
number of adverse gastrointestinal (GI) and renal side effects are
associated with their usage. The most prevalent GI side effects
PLOS ONE | www.plosone.org
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Table 1. Total body, kidney, and heart weight with organ to body ratio.

Group

Body (g)

Kidney (g)

Kidney/Body

Heart (g)

Heart/Body
0.003660.0001

VEH+VEH

250.1065.23

0.8860.06

0.003560.0002

0.9060.04

VEH+CEL

244.0068.04

0.7960.05

0.003360.0002

0.9160.03

0.003860.0002

MISO+MISO

240.6765.71

0.8960.07

0.003760.0002

0.9360.03

0.003960.0001

MISO+CEL

260.6066.79

0.8260.05

0.003160.0002

1.0060.07

0.003960.0004

VEH+VEH – vehicle+vehicle; VEH+CEL – vehicle+celecoxib; MISO+MISO – misoprostol+misoprostol; MISO+CEL – misoprostol+celecoxib.
The values were not significantly different, p.0.05.
doi:10.1371/journal.pone.0089087.t001

University, experimental procedures were carried out on male
Sprague-Dawley rats, ranging in weight from 240 to 290 g,
following an UCAC reviewed and approved protocol (#P110901).
GPower 3.1, a software program which determines statistical
power, was used to identify an appropriate study sample size. The
effect size based on a previous study, which revealed a 65625%
(mean 6 standard deviation) sodium excretion decrease in rats
treated with celecoxib, was 40% [27]. Using an effect size of 0.4
and a power of 95%, the detection of a significant difference (p,
0.05) in sodium excretion rate required a sample size of 24. Thus
this study consisted of 4 groups (n = 6).
Celecoxib or misoprostol was dissolved in a 0.5% methylcellulose solution and administered via gastric intubation. A significant
change in electrolyte excretion has been previously reported with a
celecoxib dose of 40 mg/kg/day [28]. Therefore, in the present
study, animals received the same drug dosage. Kurtz et al. have
demonstrated an increase in blood pressure one week following
treatment with a COXIB (rofecoxib) in normotensive rats [29].
Therefore, we administered celecoxib for one week. The dosage of
misoprostol (200 mg/kg/day) was chosen based on data published
by Ozer et al. [30].

urinary sodium excretion has been shown to be associated with an
increased risk of CV events [15,16]. In a systematic review
conducted by McGettigan and Henry, celecoxib was found to
confer an overall increase in CV risk with doses exceeding
400 mg/day [12]. This dose-dependent relationship between
celecoxib and CV risk was also uncovered in a meta-analysis by
Solomon et al. which exhibited an increase in the relative risk of
CV events as the daily dose of celecoxib increased from 400–
800 mg [11].
Misoprostol is a synthetic analogue of PGE1 that has gained
considerable attention as a powerful reactive oxygen species
scavenger [17] showing strong anti-apoptotic and cytoprotective
effects [18]. Over the years, misoprostol use has been successful in
the treatment of liver cell necrosis and intestinal cell apoptosis and
has been approved by the FDA for the treatment of NSAIDrelated GI side effects [17,19–22]. The gastroprotective effects of
misoprostol were first described by Robert et al. in 1967, and have
become the active standard against which newer gastroprotective
interventions are tested. As such, misoprostol is commonly used for
the prevention of deleterious GI side effects of NSAIDs such as
diclofenac (a non-selective NSAID) [19,23,24].
Misoprostol has also been found to affect the expression of
NKCC2 [25] through cyclic adenosine monophosphate (cAMP)
regulation. NSAIDs consumption reduces PGE2 levels through
COX inhibition, which decreases cAMP expression, allowing for
increased NKCC2 expression. Misoprostol has been shown to
reverse the stimulatory effects of NSAIDs on NKCC2 expression
[26].
The objective of this study was to evaluate the effect of
misoprostol on celecoxib-induced renal toxicity. Furthermore, the
CV effects of celecoxib alone or in combination with misoprostol
were examined.

The Study Design
On day 0, rats were divided into 4 groups (n = 6). On days 1 and
2, vehicle+vehicle (control) and vehicle+celecoxib groups were
dosed with vehicle (methylcellulose solution) twice daily. The
misoprostol+misoprostol and misoprostol+celecoxib groups were
dosed with misoprostol (100 mg/kg) twice daily. On days 3–9, the

Materials and Methods
Chemicals
High performance liquid chromatography (HPLC) grade
chemicals (iso-octane, 2-propanol, acetonitrile, water, acetic acid,
sulfuric acid, and triethanolamine) were purchased from Fischer
Scientific Laboratory (Fair Lawn, NJ, USA). Celecoxib was
purchased from Toronto Research Chemicals, Inc. (North York,
ON, Canada); while Methylcellulose 4000 was purchased from
Science Stuff, Inc. (Austin, TX, USA). Misoprostol was purchased
from the Cayman Chemical Company (Ann Arbor, MI, USA) and
ibuprofen was obtained from Sigma-Aldrich (St. Louis, MO,
USA).

Figure 1. Effect of treatment with vehicle+vehicle (VEH+VEH),
vehicle+celecoxib (VEH+CEL), misoprostol+misoprostol (MISO+MISO), or misoprostol+celecoxib (MISO+CEL) on sodium
excretion rate. *p,0.05, significantly different from baseline. "p,
0.05, significantly different from day 2. #p,0.05, significantly different
from VEH+VEH. +p,0.05, comparison of VEH+CEL group with MISO+
CEL group.
doi:10.1371/journal.pone.0089087.g001

Animals and Drug Administration
In accordance with guidelines established by the University
Committee on Animal Care (UCAC) at East Tennessee State
PLOS ONE | www.plosone.org
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vehicle+vehicle group received vehicle twice daily. The vehicle+
celecoxib group received a single daily dose of celecoxib (40 mg/
kg) in the morning and vehicle once daily in the afternoon. The
misoprostol+misoprostol group received misoprostol (100 mg/kg)
twice daily. The misoprostol+celecoxib group received misoprostol
(100 mg/kg) twice daily along with a single daily dose of celecoxib
(40 mg/kg). On days 0, 2, 3, and 9, animals were transferred to
metabolic cages and housed 8 hours (from 8 a.m. to 4 p.m.) for
urine sample collection. Following urine collection, blood samples
(500 mL) were taken via the tail clip method into a capillary blood
collection tube containing lithium heparin. The tube was then
centrifuged at 12,000 rpm for 3 minutes. The supernatant was
transferred to a microcentrifuge tube and kept at 280uC until
analysis. During the study, blood pressure measurements were
obtained by using a two channel, non-invasive, tail-cuff blood
pressure monitoring system (Kent Scientific, Torrington, CT). On
day 10 under anesthesia, blood was collected via heart puncture
through the diaphragm. The heart, liver, and kidneys were
excised, snap frozen, and stored at 280uC for analysis.

Figure 2. Effect of treatment with vehicle+vehicle (VEH+VEH),
vehicle+celecoxib (VEH+CEL), misoprostol+misoprostol (MISO+MISO), or misoprostol+celecoxib (MISO+CEL) on potassium
excretion rate. *p,0.05, significantly different from baseline. "p,
0.05, significantly different from day 2. #p,0.05, significantly different
from VEH+VEH. `p,0.05, comparison of MISO+MISO group with MISO+
CEL group.
doi:10.1371/journal.pone.0089087.g002

Electrolyte Analysis
The levels of sodium and potassium in plasma or urine were
determined using an EasyLyte analyzer (Medica Corporation,
Bedford, MA, USA). Urinary ion excretion rates were determined
using an equation, C6V6100/T6W, which involves the detected
concentration (mmol/L) of Na+ or K+ in the urine sample, the
total urine volume in milliliters (V), collection time in minutes (T),
and the body weight of the animal in grams (W).

stop solution was added to each well. The plate was read at
405 nm with a 490 nm differential filter. Curve-fitting was
performed using the 3rd order polynomial regression of the
cloud-based data analysis software (MyAssays Ltd, Sussex,
England).

Determination of Aldosterone Levels
Plasma aldosterone levels were measured using an aldosterone
enzyme immunoassay (BioVendor, Asheville, NC, USA). Frozen
plasma samples were thawed at room temperature. Then 50 mL of
calibrator solution, control solution, and plasma samples were
pipetted into correspondingly labelled wells in duplicate. Afterward, 100 mL of conjugate working solution was pipetted into each
well using a multichannel pipette. The plate was then incubated at
room temperature on a plate shaker set at 200 rpm for 1 hr.
Following incubation, each well was washed 3 times with 300 mL
of diluted wash buffer. After washing, 150 mL of TMB substrate
was pipetted into each well and incubated for 20 minutes, after
which 50 mL stop solution was added. The plate was immediately
read at 450 nm. Cloud-based data analysis software was used to
generate a standard curve using an exponential fit.

Determination of Urinary Kidney Injury Molecule-1 (KIM1) Concentrations
Urinary KIM-1 levels were assessed using an enzyme-linked
immunosorbent assay (ELISA) in accordance with manufacturer
instructions (Rat KIM-1 ELISA Test Kit, Kamiya Biomedical
Company, Seattle, WA, USA) [31,32]. The frozen urine samples
were thawed; allowed to come to room temperature; and then
diluted 1:3 with the provided dilution buffer. Standard calibrators
were serially diluted from 10 to 0.313 ng/mL. In a micro-titer
plate, 50 mL of dilution buffer and 25 mL of corresponding sample
(calibrator or urine) were added to each well. Samples were
allowed to equilibrate on a rotary shaker for one minute. Fifty
microliters of each sample was then quickly transferred to
corresponding ELISA plate wells containing 50 mL of blocker/
stabilizer solution. Samples were incubated for 120 minutes and
then washed for 10 seconds, after which 100 mL of anti-KIM-1
Conjugate was added to each well. Further incubation (60
minutes) and then another wash were performed. One hundred
microliters of substrate solution was then added to the wells and
incubated for another 20 minutes. After incubation, 100 mL of
Table 2. Sodium and potassium plasma levels on day 10.

Group

Sodium (mM)

Potassium (mM)
6.2660.72

VEH+VEH

134.1660.91

VEH+CEL

136.8061.56

4.8960.66

MISO+MISO

136.0860.66

5.6860.60

MISO+CEL

136.6861.01

4.9960.33

Figure 3. Effect of treatment with vehicle+vehicle vehicle
(VEH+VEH), vehicle+celecoxib (VEH+CEL), misoprostol+misoprostol (MISO+MISO), or misoprostol+celecoxib (MISO+CEL) on
KIM-1 concentration. *p,0.05, significantly different from baseline.
"
p,0.05, significantly different from day 2. #p,0.05, significantly
different from placebo. ¥p,0.05, significantly different from day 3.
doi:10.1371/journal.pone.0089087.g003

VEH+VEH – vehicle+vehicle; VEH+CEL – vehicle+celecoxib; MISO+MISO –
misoprostol+misoprostol; MISO+CEL – misoprostol+celecoxib.
The values were not significantly different, p.0.05.
doi:10.1371/journal.pone.0089087.t002
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Determination of Blood Urea Nitrogen (BUN)

Histopathological Assessments

Measurement of circulating BUN was carried out using a BUN
enzymatic assay kit (Bioo Scientific Corporation, Austin, TX,
USA). Briefly, 5 mL of plasma was added, in duplicate, to
designated microwell plates, followed by 150 mL of urease mix
solution. Solutions were then incubated for 15 minutes at room
temperature. Following this, 150 mL of alkaline hypochlorite was
added to each well then incubated again for another 10 minutes.
After incubation, the plate was read at 620 nm.

Kidney and heart samples were placed in 10% formalin for 24
hours. Thick sections (0.5 mm) were prepared for each heart and
each kidney then stained using hematoxylin and eosin stain (H&E).
Each slide was reviewed by a board certified anatomic and clinical
pathologist who was unaware of treatment groups.
The kidney was evaluated based on tubular necrosis, tubular
dilatation, and glomeruli sparing. Tubular necrosis was graded on
a scale from 0 to 3 based on the geographic area and extent of
necrotic tubules (0 = normal/no tubular necrosis, 1 = focal area of
tubular necrosis involving less than 10% of the kidney, 2 = tubular
necrosis involving 10–25% of the kidney, 3 = tubular necrosis
involving greater than 25% of the kidney). Tubular dilatation was
graded on a scale of 0 to 3 (0 = normal tubules, 1 = mild dilatation,
2 = moderate dilatation, 3 = severe dilatation). Glomeruli were
examined for structural changes or damage.
The heart was evaluated for any abnormalities of the
myocardium (inflammation, infarct, and/or scarring).

Determination of Plasma Levels of Cardiac Troponin I
(cTnI)
To detect any heart injury during this study, plasma cTnI levels
were measured based on a previously described method [33] using
a K-ASSAY Rat Cardiac Tropinin-1 ELISA (Kamiya Biomedical
Company, Seattle, WA, USA). Prior to assay, plasma samples
were thawed and diluted 1:4 with the provided plasma diluent.
Lyophilized cTnI stock was reconstituted with 400 mL de-ionized
water and gently mixed over 10 minutes. Calibrators were
prepared using serial dilution (10, 5, 2.5, 1.25, 0.625, 0.312,
0.156 ng/mL). Plasma samples and calibrators were used within
30 minutes of preparation. One hundred microliters of cTnI HRP
conjugate was added to each well followed by either 100 mL of
calibrator or diluted sample. The plate was placed on a shaker
(150 rpm) at room temperature for one hour. Plate contents were
emptied and the micro-titer wells were rinsed six times with 1X
wash solution. Residual droplets of wash solution were removed by
striking the plate on a paper towel. Following the addition of
100 mL of tetramethylbenzidine to each well, the plate was placed
on a plate shaker (150 rpm) for 20 minutes at room temperature.
Stop solution (100 mL) was then added to each well and mixed
gently. The plate was read at 450 nm.

TUNEL Assay
Slides were assayed for apoptosis using an In Situ Cell Death
Detection Kit, Fluorescein following manufacturer instructions
(Roche Applied Science, Mannheim, Germany). Briefly, sections
were isolated using a pap pen and washed with PBS. The tissue
was incubated in permeabilizing solution (0.01% Triton-X in
0.01% Sodium Citrate) at room temperature for 8 minutes.
Following PBS washing, 50 mL assay solution was added to each
section then incubated at 37uC for one hour. The slides were
washed with PBS then stained with DAPI for five minutes at room
temperature. Following a final PBS wash, the slides were partially
dried. Coverslips were applied to each slide following application
of ProLongH Gold Antifade Reagent (Life Technologies, Grand
Island, NY). Samples were allowed to dry then fluorescent images
(20x magnification) were captured using an EVOS fluorescent
microscope (AMG, Bothell, WA).
Images were quantified using apoptotic cell percentage. Six
slide-representative sections (3 containing tubules and 3 containing
glomeruli) were counted (nuclei and TUNEL positive) for each
animal.

Blood Pressure Measurements
Using the CODA Standard Non-Invasive Blood Pressure
System (Kent Scientific, Torrington, CT, USA), blood pressure
parameters were obtained using a tail-cuff method described by
Whitesall et al. [34]. Briefly, the rat was placed in a box restraint. A
tail-cuff occluder was placed on the tail which passed through an
optical sensor. The cuff was inflated then deflated slowly creating
an occlusion followed by reperfusion detected by the sensor. The
instrument was controlled by software which used measurements
from a series of inflation-deflation cycles to calculate blood
pressure.

Immunohistochemistry
Slide preparation. Paraffin-embedded kidney sections
(4 mm) were prepared for TUNEL assay and immunohistochemistry. Slides were deparaffinized using xylene, graded ethanol

Figure 4. Effect of treatment with vehicle+vehicle (VEH+VEH), vehicle+celecoxib (VEH+CEL), misoprostol+misoprostol (MISO+MISO), or misoprostol+celecoxib (MISO+CEL) on aldosterone concentrations. The values were not significantly different, p.0.05.
doi:10.1371/journal.pone.0089087.g004
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Figure 5. Effect of treatment with vehicle+vehicle (VEH+VEH), vehicle+celecoxib (VEH+CEL), misoprostol+misoprostol (MISO+MISO), or misoprostol+celecoxib (MISO+CEL) on BUN. The values were not significantly different, p.0.05.
doi:10.1371/journal.pone.0089087.g005

5% goat serum) overnight at 4uC. Following overnight incubation,
the slides were washed for five minutes in PBS three times. The
slides were then incubated in biotinylated secondary antibody
(1:1000, dilution in PBS) for 10 minutes; washed in PBS three
times for 2 minutes; then incubated in streptavidin-peroxidase
conjugate for 10 minutes. The slides were then washed twice for
two minutes in PBS. AEC substrate was added and monitored for
intensity. Upon completion, the reaction was stopped with dH2O
(pH 8). Hematoxylin counterstain was added for 3 minutes then
washed with PBS for 5 minutes. The slides were rinsed with dH2O
(pH 8). GVA was added to the slide then coverslipped and sealed
with Cytoseal. Slides were photographed using a Spot insight 4
camera and software (Leica Leitz Labor-Lux S, 40x objective).

concentrations (100, 95, 70, 50, and 30%), and double distilled
water then incubated in PBS.
Immunohistochemical analysis, caspase-3. Slides were
incubated in peroxo-block for 2 minutes at room temperature then
washed twice for two minutes in PBS. The slides were incubated in
5% goat serum for 15 minutes then rabbit anti-caspase-3 (1:20,
dilution in 5% goat serum) overnight at 4uC. Following overnight
incubation, the slides were washed for five minutes in PBS three
times. The slides were then incubated in biotinylated secondary
antibody (1:1000, dilution in PBS) for 10 minutes; washed in PBS
three times for 2 minutes; then incubated in streptavidinperoxidase conjugate for 10 minutes. The slides were then washed
twice for two minutes in PBS. AEC substrate was added and
monitored for intensity. Upon completion, the reaction was
stopped with dH2O (pH 8). Hematoxylin counterstain was added
for 3 minutes then washed with PBS for 5 minutes. The slides were
rinsed with dH2O (pH 8). GVA was added to the slide then
coverslipped and sealed with Cytoseal. Slides were photographed
using a Spot insight 4 camera and software (Leica Leitz Labor-Lux
S, 40x objective).
Immunohistochemical analysis, NKCC2. Slides were incubated in peroxo-block for 2 minutes at room temperature then
washed twice for two minutes in PBS. The slides were incubated in
5% goat serum for 15 minutes then primary antibody, rabbit antiSLC12A1 N-term (GeneTex, Irvine, CA, USA; 1:500 dilution in

Kidney Tissue Preparation and Immunoblotting
Kidney tissue preparation. NKCC2 and NKA abundance
were measured in the kidney using a modified method published
by Fernandez-Llama et al. [26] with major changes. One half of a
kidney was placed in a 1.5 mL eppendorf tube then placed on ice.
After 10 minutes, 1 mL of isolation buffer consisting of 250
millimolar (mM) sucrose, 10 mM triethanolamine, and HaltTM
Protease and Phosphatase Inhibitor Single-Use Cocktail (Thermo
Scientific, Rockford, IL, USA) was added to each tube. Samples
were then homogenized at high speed using a Power Gen 125
electric homogenizer (Fischer Scientific, Pittsburgh, PA, USA) for
40 seconds on ice. Following homogenization, the samples were
centrifuged using a cell sifter. Protein concentrations were then
determined using a Pierce BCA Assay kit (Thermo Fischer,
Rockford, IL, USA).
NKCC2 immunoblotting. Samples were diluted to a
1.25 mg/mL protein concentration using 2X laemelli sample
buffer. Samples were vortex mixed, spun down briefly, and then
heated at 60 degrees for 15 minutes. Following removal from heat,
samples were maintained at room temperature for 5 minutes then
spun down. Five microliters of precision plus pre-stained standard
(Bio-Rad Laboratories, Hercules, CA, USA) and 20 mL of each
sample were loaded into a Tris-Acetate 3–8% gel (Life Technologies, Carlsbad, CA, USA). The gel was electrophoresed at 150
volts for 1 hour in 1X Tris-acetate running buffer containing
500 mL of NuPage antioxidant (Invitrogen, Grand Island, NY,
USA). The proteins were then transferred on to a nitrocellulose
membrane at 40 volts for 2 hours. Following transfer, the
membrane was stained with amido black for 5 minutes to visualize
protein. Following destaining with DI H2O, the membrane was

Figure 6. Effect of treatment with vehicle+vehicle (VEH+VEH),
vehicle+celecoxib (VEH+CEL), misoprostol+ misoprostol (MISO+MISO), or misoprostol+celecoxib (MISO+CEL) on cTnI. *p,
0.05, significantly different from baseline. #p,0.05, significantly
different from VEH+VEH.
doi:10.1371/journal.pone.0089087.g006
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Table 3. Blood pressure parameters measured on day 9.

Group

Diastolic pressure (mmHg)

Systolic pressure (mmHg)

Mean pressure (mmHg)

Heart rate (beats/min)

VEH+VEH

92.3562.44

141.1361.79

108.1262.02

427.9669.31

VEH+CEL

91.6463.27

144.9063.40

109.0363.14

448.26615.00

MISO+MISO

98.4163.28*

151.7662.49*

115.8962.84*#

447.97610.52

MISO+CEL

103.7063.06*#+

149.1162.31*

118.5562.67*#

446.55610.55

VEH+VEH – vehicle+vehicle; VEH+CEL – vehicle+celecoxib; MISO+MISO – misoprostol+misoprostol; MISO+CEL – misoprostol+celecoxib.
*p,0.05, significantly different from VEH+VEH.
#
p,0.05, significantly different from VEH+CEL.
+
p,0.05, comparison of VEH+CEL group with MISO+CEL group.
doi:10.1371/journal.pone.0089087.t003

of each sample were loaded into a Tris-HEPES-SDS gel (Thermo
Scientific Pierce, Rockford, IL, USA). The gel was electrophoresed
at 100 volts for 1 hour in 1X HEPES running buffer. The proteins
were then transferred on to a nitrocellulose membrane at 30 volts
for 2 hours. Following transfer, the membrane was stained with
amido black for 5 minutes to visualize protein. Following
destaining with DI H2O, the membrane was incubated with 1%
BSA in phosphate buffered saline with Tween-20 (PBST) for 1
hour.
The nitrocellulose membrane was then cut into two pieces (top
and bottom); top one containing the N-K-ATPase band
(<100 kDa) and bottom one containing b-actin (42 kDa). The
top portion was probed with rabbit polyclonal primary antibody
against NKA a-1 (GeneTex, Irvine, CA, USA; 1:500 dilution in
1% BSA); while the bottom portion was probed with goat
polyclonal primary antibody against b-Actin (Santa Cruz Biotechnology, Dallas, TX, USA; 1:500 dilation in 1% BSA). After an
overnight incubation at 4uC, the blots were rinsed 3 times with
PBST for 10 minutes. The first blot was then probed with goat
anti-rabbit HRP secondary antibody 1:5000 (Thermo Scientific,
Rockford, IL, USA) and the second blot was probed with
Peroxidase-AffiniPure donkey anti-goat secondary antibody
1:5000 (Jackson ImmunoResearch Laboratories, Inc., West Grove,
PA, USA) for 3 hours at 4uC. Following secondary antibody
probing, the blots were rinsed 3 times for 10 minutes with PBST.
Following the final PBST wash, ECL SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific, Rockford, IL,
USA) was added to the membrane and immediately placed in a GBox Imager (Syngene, Fredrick, MD, USA) for detection. The
images were analyzed using NIH software. NKA band intensities
were normalized to b-Actin band intensities to normalize for
possible protein loading fluctuations.

incubated with 2.5% BSA in phosphate buffered saline with
Tween-20 (PBST) for 1 hour.
The nitrocellulose membrane was then cut into two pieces (top
and bottom); top one containing the NKCC2 band (161 kDa) and
bottom one containing b-actin (42 kDa). The top portion was
probed with rabbit polyclonal primary antibody against NKCC2
(GeneTex, Irvine, CA, USA; 1:400 dilution in PBST); while the
bottom portion was probed with goat polyclonal primary antibody
against b-actin (Santa Cruz Biotechnology, Dallas, TX, USA;
1:500 dilation in PBST). After overnight incubation at 4uC, the
blots were rinsed 3 times with PBST for 10 minutes. The first blot
was then probed with goat anti-rabbit HRP secondary antibody
1:5000 (Thermo Scientific, Rockford, IL, USA) and the second
blot was probed with Peroxidase-AffiniPure donkey anti-goat
secondary antibody 1:5000 (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) for 3 hours at 4uC. Following
secondary antibody probing, the blots were rinsed 3 times for 10
minutes with PBST.
Following the final PBST wash, ECL SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific, Rockford, IL,
USA) was added to the membrane and immediately placed in a GBox Imager (Syngene, Fredrick, MD, USA) for detection. The
images were analyzed using NIH software. NKCC2 band
intensities were normalized to b-Actin band intensities to
normalize for possible protein loading fluctuations.
NKA Immunoblotting. Samples were diluted to a 1.25 mg/
mL protein concentration using 2X Laemelli sample buffer.
Samples were vortex mixed, spun down briefly, and then heated
at 60 degrees for 15 minutes. Following removal from heat,
samples were maintained at room temperature for 5 minutes then
spun down. Three microliters of precision plus pre-stained
standard (Bio-Rad Laboratories, Hercules, CA, USA) and 20 mL
Table 4. Assessment of tubular necrosis and dilatation.

Tubular Necrosis Score

Tubular Dilatation Score

Group

0

1

2

3

n

Mean-Rank

0

1

2

3

n

Mean-Rank

VEH+VEH

5

0

0

0

5

35.0

4

1

1

0

6

45.0

VEH+CEL

3

2

1

0

6

67.0#

2

3

1

0

6

61.5#

MISO+MISO

5

0

0

0

5

35.0

0

5

0

0

5

69.0#

MISO+CEL

0

0

2

2

4

70.0#`

0

0

4

0

4

78.0+#

VEH+VEH – vehicle+vehicle; VEH+CEL – vehicle+celecoxib; MISO+MISO – misoprostol+misoprostol; MISO+CEL – misoprostol+celecoxib.
#
p,0.05, significantly different from VEH+VEH.
`
p,0.05, comparison of MISO+MISO group with MISO+CEL group.
+
p,0.05, comparison of VEH+CEL group with MISO+CEL group.
doi:10.1371/journal.pone.0089087.t004
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Figure 7. Kidney sections (40X) from vehicle+vehicle group showing glomeruli (*) and normal tubules (arrow) without dilation or
necrosis. (A), vehicle+celecoxib group showing areas of moderate tubule necrosis (arrowhead) and mild tubule dilatation (arrow) (B), misoprostol+
misoprostol group showing mild tubular dilatation (arrow) without necrosis (more normal tubules are seen to the right of the photomicrograph) (C),
misoprostol+celecoxib group showing a large area of marked tubule necrosis (arrowhead) with relative sparing of the glomeruli (*), and moderate
tubular dilation (arrow) (D).
doi:10.1371/journal.pone.0089087.g007

Each solution was vortex mixed for 30 seconds and then
centrifuged for 5 minutes at 2,500 g. Following centrifugation,
the aqueous phase was frozen using a dry ice/ethanol bath. Each
liquid organic phase was then transferred to a clean tube for
evaporation. The samples were reconstituted using 200 mL mobile
phase. Samples (100 mL each) were injected into the HPLC system
and ran for 15 minutes using a mobile phase flow rate of 1 mL/
min. The minimal detectable concentration of celecoxib in plasma
was 25 ng/mL with a coefficient of variance of 4.2%.
Renal celecoxib extraction. Following removal from 2
80uC and subsequent thawing at room temperature, kidney
samples (one half of each kidney) were homogenized in HPLC
grade water (2:1 water, sample weight ratio). For the calibration
curve, blank kidney homogenate (100 mL) was added to clean glass
tubes then spiked with 100 mL of standard celecoxib concentrations (25–100,000 ng/mL). Two hundred microliters of 0.6 M
sulfuric acid, 100 mL internal standard, and 5 mL iso-octane 2propanol (95:5) were then added to each sample. Samples were
vortex mixed for 30 seconds followed by centrifugation at 2,500 g
for 5 minutes. A dry ice/ethanol bath was then used to freeze each
aqueous phase which allowed the removal of each organic phase
to a new glass tube. Samples were evaporated to dryness then
reconstituted with 200 mL mobile phase. Samples (100 mL each)
were injected into the HPLC. Each sample was ran at a mobile

Chromatographic Conditions
Prior to
usage, the celecoxib extraction mobile phase, composed of
acetonitrile, water, acetic acid, and triethanolamine (47:53:
0.1:0.03), was filtered using a 0.5 mm nylon filter. Serial dilutions
(25–100,000 ng/ml) of stock celecoxib solution (10 mg in 100 mL
mobile phase) were used to create a standard concentration curve.
An internal standard was prepared by dissolving ibuprofen (10 mg)
in 100 mL mobile phase. Cardiac and renal samples were
homogenized using a Power Gen 125 electric homogenizer
(Fischer Scientific, Pittsburgh, PA, USA). Sample organic phases
were evaporated using a CentriVap concentrator (Lab Conoco,
Kansas City, MO, USA). A HPLC system (Shimadzu, Japan)
consisting of a LC020AB solvent delivery system, a SIL-20A HT
auto-sampler with a SPD-M20A photodiode array detector set at
254 nm, a CBM-20A communication bus, a DGU-20A3 vacuum
degasser, and a CTO-20A column oven containing a C18
analytical column (10064.6 mm, 2.6 mm; Phenomenex, Torrance,
CA, USA) was used to determine drug concentrations.
Plasma celecoxib extraction. For plasma extraction,
100 mL of standard celecoxib concentrations (25–100,000- ng/
mL) was added to 100 mL blank rat plasma. After which, 200 mL
sulfuric acid (0.6 M), 100 mL of internal standard, and 5 mL of
iso-octane 2-propanol (95:5) was added to each standard sample.
Assay solution preparation and equipment.
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Figure 8. Cross section (40X) of normal cardiac myocytes from vehicle+vehicle group. (A), vehicle+celecoxib group showing a mild
organizing pericarditis (*) and adjacent normal cardiac myocytes (arrow) (B), normal cardiac myocytes from misoprostol+misoprostol group (C),
misoprostol+celecoxib group showing a severe organizing pericarditis (*), and adjacent normal cardiac myocytes (arrow) (D).
doi:10.1371/journal.pone.0089087.g008

vortexed 30 seconds and centrifuged for 5 minutes at 2,500 g.
Samples were then immersed in a dry ice/ethanol bath. The
organic phase was transferred to a clean glass tube and evaporated
to dryness. After which, samples were reconstituted in 200 mL
mobile phase and vortex mixed. Samples (100 mL each) were
injected into the HPLC and ran for 15 minutes with a flow rate of
1 mL/min. The minimum detectable concentration of cardiac
celecoxib was 100 ng/g exhibiting a coefficient of variance of
0.1%.

phase flow rate of 1 mL/min for 15 minutes. The minimum
detectable concentration of celecoxib was 100 ng/g in kidney
homogenates (coefficient of variance = 16.2%).
Cardiac celecoxib extraction. Heart samples (one half of
each heart) were removed from 280uC and thawed at room
temperature. Each sample was transferred to a clean tube,
weighed, and homogenized in a 2:1 HPLC grade water to sample
weight ratio. One hundred microliters of blank heart homogenate
was added to 100 mL of each standard celecoxib dilution (25–
100,000 ng/mL). Two hundred microliters sulfuric acid (0.6 M)
was added to each sample followed by 100 mL internal standard.
After adding 5 mL of iso-octane 2-propanol (95:5), samples were

Data Treatment and Statistical Analysis
For the urinary electrolyte excretion rates, KIM-1 concentrations, and cTnI levels, data comparisons among the groups were
made by two-way ANOVA, using the PROC MIXED procedure
of SAS (SAS Institute Inc., Cary, NC, USA). For weight
parameters, plasma electrolyte, aldosterone, and BUN levels,
and blood pressure parameters, one-way ANOVA was used to
compare groups. For NKCC2 and NKA abundance, comparisons
were conducted using the mean control ratio as a standard for all
experimental mean ratios. Ratios from all samples were analyzed
using one-way ANOVA. Kruskal-Wallis one way analysis,
followed by a post hoc test, was performed for histologic scores.
TUNEL assay tubule and glomerular group percentage means
were analyzed among experimental groups using one-way
ANOVA.
For celecoxib concentration levels, data analysis was completed
using a Student’s t-test. Statistical significance was conferred at p,

Table 5. Quantification of apoptosis levels within glomeruli
and tubules.

Group

Glomeruli

Tubules

VEH+VEH

31.7962.26

28.2161.99

VEH+CEL

33.8263.31

21.9463.09

MISO+MISO

30.4862.57

20.1261.95

MISO+CEL

36.9163.62

25.9663.22

VEH+VEH – vehicle+vehicle; VEH+CEL – vehicle+celecoxib; MISO+MISO –
misoprostol+misoprostol; MISO+CEL – misoprostol+celecoxib. Values presented
as mean apoptotic cell percentage 6 SEM.
The values were not significantly different, p.0.05.
doi:10.1371/journal.pone.0089087.t005
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Figure 9. Glomerular TUNEL assay consisting of DAPI (nuclei), fluorescein (apoptotic marker), and merged sections for each group
(vehicle+vehicle (A); vehicle+celecoxib (B); misoprostol+misoprostol (C); misoprostol+celecoxib (D)). 20x magnification.
doi:10.1371/journal.pone.0089087.g009

0.05. Values are represented as mean 6 standard error of the
mean.

(0.6160.06 versus 0.3760.06 ng/mL, p = 0.0015) on day 3. At
day 9, vehicle+celecoxib (0.5660.10) treated rats showed significantly increased KIM-1 expression compared to both baseline
(0.3560.07, p = 0.0106) and day 2 (0.3260.02, p = 0.0036) values,
while animals treated with misoprostol+misoprostol (0.3060.03)
show significantly reduced KIM-1 levels in comparison to day 3
(0.5060.10, p = 0.0090). No significant difference was noted in
KIM-1 levels between vehicle+celecoxib and misoprostol+celecoxib groups (p = 0.6624).

Results
Effect of Drugs on Body, Heart, and Kidney Weight
To determine drug effects on organ and body mass, animals
were weighed on day 10 prior to euthanasia. The heart and
kidneys were excised and weighed before experimental analysis.
Animal body weight ranged from 240.6765.71 to 260.6066.79
(Table 1). There was no significant difference between total
bodyweight of any of the treatment groups (p = 0.1785). Heart and
kidney weights did not fluctuate to any significant degree by the
end of the study (p = 0.4547 and p = 0.5618, respectively) and no
significant alterations in heart to bodyweight or kidney to
bodyweight ratios were noted (p = 0.7814 and p = 0.2073,
respectively).

Effect of Drugs on Aldosterone
To determine probable cause of electrolyte retention, circulating aldosterone levels on day 10 were measured using blood
collected via heart puncture. As has been indicated in Figure 4,
final day aldosterone plasma concentrations ranged from
197.49680.59 to 277.266143.93 pg/mL. No significant difference was noticed among the treatment groups (p = 0.8269).

Effect of Drugs on Electrolyte Excretion Rates and Plasma
Levels

Effect of Drugs on BUN Concentration
To determine the extent of uremia within treatment groups,
BUN levels on day 10 were measured using blood collected via
heart puncture. Treatment of misoprostol, celecoxib or their
combination did not increase BUN levels any appreciable degree
among treatment groups (p = 0.4225) (Figure 5). Average BUN
concentrations ranged from 7.8560.35 to 6.6860.49 mg/dl
(Figure 5).

To determine drug effects on electrolyte excretion, urinary
samples collected on days 0, 2, 3 and 9 and plasma samples
collected on day 10 were analyzed with an EasyLyte electrolyte
analyzer. Baseline values ranged from 0.1860.01 mmol/min/
100 g to 0.2360.04 mmol/min/100 g (Figure 1). On day 2,
urinary excretion of sodium was significantly reduced in the
misoprostol+misoprostol
(0.1260.05 mmol/min/100 g,
p = 0.0037) and misoprostol+celecoxib (0.0760.02 mmol/min/
100 g, p = 0.0006) groups when compared to baseline
(0.2260.03 mmol/min/100 g and 0.1960.03 mmol/min/100 g,
respectively). At day 3, all treatment groups began showing
significant reductions in sodium excretion when compared to
baseline. Groups receiving vehicle+celecoxib (0.0360.002 mmol/
min/100 g) or misoprostol+celecoxib (0.0360.005 mmol/min/
100 g) showed significant reduction in sodium excretion when
compared to vehicle+vehicle (0.1560.033 mmol/min/100 g, p,
0.01). By day 9, all treatment groups showed significant reductions
in sodium excretion compared to control.
Potassium excretion was significantly lower in vehicle+celecoxib
and misoprostol+celecoxib groups when compared to baseline
(Figure 2). At day 3, potassium excretion was significantly lower in
the misoprostol+celecoxib group (0.0960.03 mmol/min/100 g)
when compared to both baseline (0.2360.02 mmol/min/100 g,
p = 0.0011), day 2 (0.1960.03 mmol/min/100 g, p = 0.0140) and
vehicle+vehicle (0.1860.04 mmol/min/100 g, p = 0.0267) values.
Potassium excretion was significantly reduced in comparison to
baseline for both the vehicle+celecoxib group (0.2360.01 mmol/
min/100 g versus 0.1360.01 mmol/min/100 g, p = 0.0456) and
the misoprostol+celecoxib group (0.2360.02 mmol/min/100 g
versus 0.1260.03 mmol/min/100 g, p = 0.0126) through day 9.
Comparisons of electrolyte plasma values showed no significant
changes in sodium (p = 0.3128) or potassium (p = 0.3838) levels for
any treatment group (Table 2).

Effect of Drugs on cTnI
To evaluate the effects of celecoxib and/or misoprostol on CV
health, cTnI assays were performed to measure the extent of cTnI
expression at baseline, day 2, day 3 and day 9 (Figure 6). On day
3, rats treated with vehicle+celecoxib had significant increases in
cTnI expression when compared to baseline and vehicle+vehicle
(p = 0.0467 and p = 0.0171, respectively). At day 9, vehicle+
celecoxib treated groups maintained elevated cTnI levels in
comparisons to baseline and vehicle+vehicle (p = 0.0203 and
p = 0.0040, respectively); while the misoprostol+misoprostol group
showed a significant elevation in cardiac cTnI expression when
compared to vehicle+vehicle (p = 0.0078). No significant differences were noted among the treatment groups at any time point.

Effect of Drugs on Blood Pressure Parameters
To measure the cardiac effects of celecoxib and misoprostol,
blood pressure measurements were taken for each group (Table 3).
On day 9, there were no significant differences in blood pressure
parameters between the vehicle+celecoxib group and the vehicle+
vehicle group. The misoprostol+misoprostol group showed significant increases in systolic (p = 0.0017) and mean blood pressure
(p = 0.0304) when compared to the vehicle+vehicle group; while
rats receiving misoprostol+celecoxib showed significant increases
in diastolic (p = 0.0054), systolic (p = 0.0171), and mean blood
pressure (p = 0.0036). When compared to vehicle+celecoxib, rats
treated with misoprostol+celecoxib showed significant increases in
diastolic and mean blood pressure (p = 0.0071 and p = 0.0153,
respectively).

Effect of Drugs on Urinary KIM-1 Concentrations
As shown in Figure 3, baseline KIM-1 levels ranged from
0.3560.07 to 0.3860.05 ng/mL. Compared to the baseline
values, a significant increase in KIM-1 levels was observed in
both the vehicle+celecoxib group (0.6560.02 versus
0.3560.07 ng/mL, p = 0.0002) and misoprostol+celecoxib group
PLOS ONE | www.plosone.org
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In the kidney, no significant histopathological changes were
noted in the glomeruli (Figure 7). However, groups receiving
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Figure 10. Tubular TUNEL assay consisting of DAPI (nuclei), fluorescein (apoptotic marker), and merged sections for each group
(vehicle+vehicle (A); vehicle+celecoxib (B); misoprostol+misoprostol (C); misoprostol+celecoxib (D)), 20x magnification.
doi:10.1371/journal.pone.0089087.g010

Rank Score: vehicle+celecoxib versus misoprostol+celecoxib; 61.5
versus 78.0 (p,0.05).

vehicle+celecoxib or misoprostol+celecoxib showed a significant
increase in tubular necrosis compared to vehicle+vehicle (Mean
Rank Score: vehicle+vehicle versus vehicle+celecoxib, 35.0 versus
67.0 (p,0.05); vehicle+vehicle versus misoprostol+celecoxib, 35.0
versus 70.0 (p,0.05) (Table 4). All groups receiving treatment
showed significant increases in tubular dilatation; however,
dilatation was more severe in the group treated with misoprostol+celecoxib compared to the vehicle+celecoxib group (Mean

Histopathologic Assessment of the Heart
In general, no significant histopathological changes were noted
in the myocardium (Figure 8). Three animals, one in the vehicle+
celecoxib group and two in misoprostol+celecoxib group, exhib-

Figure 11. Caspase-3 immunohistochemistry consisting of an isotype control, glomerular, and tubular sections for each group
(vehicle+vehicle (A); vehicle+celecoxib (B); misoprostol+misoprostol (C); misoprostol+celecoxib (D)), 40x magnification.
doi:10.1371/journal.pone.0089087.g011
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Figure 12. NKCC2 expression (A) and normalized bands (B) in treatment with vehicle (VEH+VEH), vehicle+celecoxib (VEH+CEL),
misoprostol+misoprostol (MISO+MISO), or misoprostol+celecoxib (MISO+CEL). Each immunoblot was conducted in triplicate. The values
were not significantly different, p.0.05.
doi:10.1371/journal.pone.0089087.g012

ited a significant organizing pericarditis. However, no inflammation or changes of ischemia, infarct or myocardial injury was seen.

misoprostol+celecoxib does not significantly alter tubular nor
glomerular apoptotic levels (p = 0.144 and p = 0.485, respectively).

TUNEL Assay

Immunohistochemical Analysis of Caspase-3

Glomerular and tubular TUNEL analysis are presented visually
in Figures 9 & 10, respectively. As seen in Table 5, the
administration of vehicle+celecoxib, misoprostol+misoprostol, or

Figure 11 shows Caspase-3 immunohistochemical labeling.
There does not appear to be a significant difference in Caspase-3
abundance between treatment groups compared to control neither
within glomeruli nor tubules.

Figure 13. NKCC2 immunohistochemistry consisting of an isotype control, then one section from each group (vehicle+vehicle (A);
vehicle+celecoxib (B); misoprostol+misoprostol (C); misoprostol+celecoxib (D)) showing the presence of NKCC2 (arrows). 40x
magnification and insert at 100x.
doi:10.1371/journal.pone.0089087.g013
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Figure 14. NKA a-1 expression (A) and normalized bands (B) in treatment with vehicle (VEH+VEH), vehicle+celecoxib (VEH+CEL),
misoprostol+misoprostol (MISO+MISO), or misoprostol+celecoxib (MISO+CEL). Each immunoblot was conducted in triplicate. The values
were not significantly different, p.0.05.
doi:10.1371/journal.pone.0089087.g014

Actin ratio (normalize band densities: control, 1.0060.09; vehicle+
celecoxib, 0.9960.09; misoprostol+misoprostol, 1.0260.05; misoprostol+celecoxib, 0.9660.10; p = 0.9910) (see Figure 12B). Thus
administration of vehicle+celecoxib, misoprostol+misoprostol, or
misoprostol+celecoxib did not significantly influence the levels of
NKCC2 in these animals.

Western Blot Analysis of NKCC2 Abundance
Figure 12A displays data collected from immunoblotting of
renal NKCC2 and b-Actin. Western blot examination of whole
kidney for NKCC2 abundance revealed no significant difference
among treatment groups normalized to the control NKCC2: b-

Immunohistochemical Analysis of NKCC2

Table 6. Celecoxib concentration in the plasma, kidney, and
heart.

Immunohistochemically labeled NKCC2 is shown in Figure 13.
Compared to vehicle+vehicle, NKCC2 abundance does not
appear to change within experimental groups.

Celecoxib Concentration
Group

Plasma (mg/mL) Kidney (mg/g)

Heart (mg/g)

VEH+CEL

3.2960.78

4.6661.47

2.7661.20

MISO+CEL

2.5060.70

5.0063.18

0.6660.32

Western Blot Analysis of NKA Abundance
Figure 14A displays data collected from immunoblotting of
renal NKA and b-Actin. Western blot examination of whole
kidney for NKA abundance revealed no significant difference
among treatment groups normalized to the control NKA a-1: bActin ratio (normalize band densities: control, 1.0060.05; vehicle+
celecoxib, 0.9860.03; misoprostol+misoprostol, 1.0060.05; miso-

VEH+CEL – vehicle+celecoxib; MISO+CEL – misoprostol+celecoxib.
The values were not significantly different, p.0.05.
doi:10.1371/journal.pone.0089087.t006
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balance between total body electrolyte concentrations and plasma
volume. However, as shown in Figure 4, aldosterone levels on day
10 were not significantly altered among experimental groups
compared to control. Thus electrolyte balance is being maintained
through another mechanism. Balance may be maintained through
vasopressin and anti-diuretic hormone (ADH) alterations. When
plasma becomes concentrated, ADH is secreted in response to
increased plasma osmolarity [47]. Previous studies have shown
that ADH release is controlled by osmatic stimuli brought forth
from changes in total electrolyte balance [47,48]. It is entirely
possible that the results of our study, showing normalized plasma
electrolyte balance, is a result of alterations in hemodynamic
pathways involving ADH and other hormone cascades. The
absence of a significant change in BUN (Figure 5) in this
experiment support previous studies which indicate that while
nonselective NSAIDs produce sodium retention and a reduced
glomerular filtration rate (GFR), COXIBs do not influence GFR
[49].
KIM-1 is a sensitive and robust urinary biomarker of acute
renal injury [31]. KIM-1 is a class 1 transmembrane cellular
glycoprotein expressed by proximal tubule epithelial cells in the
presence of injury or ischemia, including injury of drug origin
[50,51]. Recent studies have shown a direct relationship between
KIM-1 expression and symptomatic heart failure in patient
populations. In one study, KIM-1 expression was increased in
patients diagnosed with chronic heart failure [52]. Another study
confirmed that an increase in KIM-1 levels predisposes elderly
men towards an increased risk of heart failure [53]. Lekawanvijit
et al. also demonstrated a cardiorenal relationship for this
biomarker, as evidenced by significant post-MI increases in
KIM-1 expression in a rat model [54]. In our study, we looked
at the possible attenuating effects of misoprostol when given in
conjunction with NSAIDs on KIM-1 expression. As shown in
Figure 3, concomitant administration of misoprostol with
celecoxib did not attenuate NSAID induced KIM-1 expression.
These findings suggest that misoprostol does not exhibit renal
protection in the presence of celecoxib.
Troponin is a protein complex found in striated muscle,
including cardiac muscle. cTnI and cardiac troponin T (cTnT) are
indicators of cardiac muscle damage in humans [55], and have
also been useful in detecting cardiac damage in rats [56,57]. In our
study, we found significant increases in cTnI expression in groups
treated with celecoxib on day 3 when compared to baseline
(Figure 6). These levels remained elevated through day 9.
Misoprostol co-administration did not attenuate the elevation of
cTnI expression to any significant degree. Interestingly, when rat
blood pressure was measured on day 9, there was a significant rise
in diastolic, systolic, and mean pressure in the misoprostol+
misoprostol group when compared to vehicle+vehicle group
(Table 3). The influence of misoprostol on blood pressure can be
explained by the renal vasoconstriction effect of misoprostol [58].
Furthermore, when misoprostol was co-administered with celecoxib, these blood pressure parameters were further elevated.
Diastolic and mean blood pressure were significantly elevated in
the misoprostol+celecoxib group compared to both the vehicle+
vehicle and vehicle+celecoxib groups. These findings suggest that
celecoxib induces CV stress as evidenced by a rise in cTnI levels
and blood pressure parameters. Our findings also suggest that
misoprostol does not exhibit any cardioprotective effects in the
presence of celecoxib, but may exacerbate celecoxib associated
CV side effects.
Renal histopathological analysis provided insight into structural
changes effected by drug administration. The relative sparing of
glomeruli suggests that primary filtration is unaffected by celecoxib

prostol+celecoxib, 1.0960.0; p = 0.446) (see Figure 14B). Thus
administration of vehicle+celecoxib, misoprostol+misoprostol, or
misoprostol+celecoxib did not significantly influence the levels of
NKA in these animals.

Levels of Celecoxib in Presence or Absence of
Misoprostol
Plasma, kidney, and heart samples were analyzed to determine
if misoprostol would alter celecoxib blood and tissue concentrations in the misoprostol+celecoxib group (Table 6). In plasma,
drug concentrations of celecoxib in the vehicle+celecoxib group
were not significantly different from those of the misoprostol+
celecoxib group (p = 0.4710). Kidney celecoxib concentrations in
vehicle+celecoxib group were not significantly different from
misoprostol+celecoxib group (p = 0.9198). Analysis of the heart
tissue showed no significant alterations in celecoxib concentration
between the vehicle+celecoxib and misoprostol+celecoxib groups
(p = 0.1446).

Discussion
NSAIDs exert their side effects (e.g. GI, renal) by reducing the
production of PGs. Celecoxib is a potent anti-inflammatory drug
that functions by selectively inhibiting the COX-2 enzyme and
subsequently reducing PG synthesis [11,35].
Misoprostol, a PG-based medicine, has been used for prevention of NSAID-induced gastric injury. Misoprostol functions as a
PGE1 analogue that offsets the deleterious effects of NSAIDs
related to a reduction in PG biosynthesis and has been effectively
used to offset gastric-related side effects often associated with
NSAID consumption [24,36–39].
The deleterious effects of NSAIDs on renal and CV systems
have been well documented and extensively studied over the years.
Interestingly, there have also been several studies that report the
beneficial and protective effects of misoprostol consumption on
CV disease formation, renal damage, and nephrotoxicity
[30,40,41]. However, few studies have analyzed the CV and
renal effects of concomitant administration of misoprostol with
NSAIDs. Although the CV effects of select NSAIDs have been
well documented [8,42], the current literature has reported
conflicting evidence in regard to the CV effects of celecoxib
[42]. This study was designed to investigate the influence of
concomitant administration of misoprostol on renal adverse effects
of celecoxib. In addition, we studied the effect of celecoxib alone
or in combination with misoprostol on some CV parameters in
rats.
Renal injury is known to initially manifest through a reduction
in electrolyte excretion and total urine outflow [43]. In past
studies, misoprostol has been shown to delay the nephrotoxic
effects of NSAIDs in cirrhotic patients and maintain normal
urinary excretion and electrolyte output [44–46]. In our present
study, we investigated the effect of misoprostol on celecoxib
induced renal impairment by measuring and comparing total
electrolyte excretion between treatment groups. Misoprostol given
at a dose of 200 mg/kg daily did not attenuate sodium retention
when given simultaneously with celecoxib (Figure 1). Likewise, the
rate of potassium retention was also unaffected by the addition of
misoprostol (Figure 2). These findings suggest that misoprostol was
unable to attenuate NSAID-induced electrolyte retention. Interestingly, no significant change in plasma electrolyte concentrations
was observed among the treatment groups. These findings are
reflective of the compensatory change in body hemodynamics
brought forth by altered renal health. Various hormones such as
aldosterone, renin, and angiotensin act to control and mediate the
PLOS ONE | www.plosone.org
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and changes in ion exchange likely occur at reuptake across the
renal tubules (Figure 7). As previously reported, administration of
celecoxib produces tubular necrosis and dilatation [59]. Concomitant misoprostol and celecoxib administration was discovered to
exacerbate tubular necrosis. Similar damage intensification has
been shown in a previous study in which celecoxib plus
paracetamol worsened renal damage compared to celecoxib alone
[60]. However, renal celecoxib levels were not increased in the
presence of misoprostol. Thus, tubular damage does not appear to
be directly correlated with renal celecoxib concentration. The
renal adverse effect intensifying property of misoprostol will need
to be weighed against the gastroprotective property conferred
through concomitant administration, especially in cases of prior
renal dysfunction.
Because misoprostol administration has presented with strong
anti-apoptotic effects, renal apoptosis was quantified to account for
renal damage [22]. As the TUNEL assay revealed no significant
change in glomeruli (Figure 9) nor tubules (Figure 10), the renal
toxicity observed in this study seems to occur primarily through
necrotic cell death. The results of Caspase-3 immunohistochemistry (Figure 11) serve as a confirmation of the TUNEL results, as
seemingly no change in abundance occurred between control and
experimental groups.
In this study, rats presenting with pericarditis were grouped
together and compared to all other celecoxib receiving rats
(Figure 8). A student’s t test of the two groups, pericarditis positive
and negative, revealed no significant difference in celecoxib
concentration between the groups (data not shown). As such, an
alteration in celecoxib concentration does not appear to be
responsible for the appearance of pericarditis. In humans,
pericardial inflammation can arise as a result of drug induced
damage, bacterial or viral infections, or MI; however, pericarditis
may also be idiopathic in origin [61]. A review of current literature
shows no previous articles which have reported pericarditis
associated with NSAID administration.
Sodium retention functions as a hallmark of NSAID-induced
renal dysfunction [62]. PGE2 reduces sodium reabsorption in the
thick ascending limb of the loop of Henle [63] via an activity
reduction in NKCC2 [64]. In the absence of PGE2, through
inhibition by NSAIDs, the presence of NKCC2 is increased;
however, misoprostol administration has been shown to reduce the
amount of NKCC2 [26]. The absence of a significant NKCC2
abundance change in this study (Figure 12) is supported by the
antagonistic effects suggested by Fernandez-Llama et al [26]. In
addition, the outcome of NKCC2 immunohistochemistry analysis
(Figure 13) was in line with our western blotting results. These
findings suggest that the particular electrolyte excretion change is
orchestrated via another mechanism. In the absence of an increase
in NKCC2 abundance, NKA was examined as a possible driver of
sodium retention [13,14]. No significant change in NKA protein
levels was detected in this experiment (Figure 14); however a
change in transporter activity, not examined in this study, could
act as a mechanism of sodium retention [13]. In previous studies,
when given concomitantly with other drugs misoprostol has been
shown to increase drug plasma concentrations significantly [65].
To test the possibility of drug-drug interactions between celecoxib
and misoprostol, we examined drug concentrations of celecoxib in
plasma and tissue samples. In this study, there was no significant

difference in celecoxib concentrations between groups treated with
vehicle+celecoxib as compared to groups treated with misoprostol+celecoxib (Table 6). These results indicate that plasma
concentrations of celecoxib were not altered in the presence of
misoprostol and that findings within our study were not a result of
pharmacokinetic drug interaction between celecoxib and misoprostol.
There are several limitations to our study. We examined the
cardiorenal side effects of celecoxib using a single daily dose of
40 mg/kg/day. At this dosage range we found significant
correlation between electrolyte excretion, kidney and cardiac
biomarker expression, and tissue necrosis in groups treated with
celecoxib or misoprostol+celecoxib. However, the observed
association between treatment groups and the accompanying side
effects may not be conclusive since it was made using a single daily
dose of our selected NSAID. Therefore, it is still unclear as to
whether these effects where reached at the ascending or plateau
stage of the drug exposure response curve. It is also important to
note that our study focused extensively on NSAID-induced
cardiorenal side effects in conjunction with misoprostol administration. The action of NSAIDs and misoprostol on NSAIDinduced GI related events has been well documented [66–68]. As
such, GI side effects were not elucidated within the context of this
study. Finally, although electrolyte excretion rates were measured,
dietary intake of electrolytes was not measured in this study. Thus
changes in excretion may result from differences in food intake
elicited by drug side effects.
In conclusion, concomitant administration of misoprostol with
celecoxib did not alter reduced electrolyte excretion induced by
celecoxib in this study. No significant difference was noticed
between the combined treatment of misoprostol and celecoxib on
KIM-1 expression. Similarly, histopathological evaluation of
kidney tissue also confirmed NSAID-induced tubular necrosis in
both treatment groups. Interestingly, celecoxib-treated groups
showed significantly elevated cTnI levels, suggesting celecoxib
induced cardiac stress. Misoprostol did not lessen cardiac stress to
any significant degree and actually showed increased cTnI levels
when compared to control. These findings suggest that misoprostol
does not attenuate NSAID-induced kidney damage and may
exacerbate cardiac stress. As such, further studies are warranted to
understand the role misoprostol and celecoxib may play in the
onset of cardiorenal events. The results obtained within this study
suggest that more research should be conducted in patients who
receive misoprostol and/or celecoxib therapy to examine for signs
of CV and renal related issues.
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